These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21530174)

  • 1. Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: focus on adenosine diphosphate receptor inhibitors.
    Ogawa H; Hokimoto S; Kaikita K; Yamamoto K; Chitose T; Ono T; Tsujita K
    J Cardiol; 2011 Jul; 58(1):6-17. PubMed ID: 21530174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current oral antiplatelets: focus update on prasugrel.
    John J; Koshy SK
    J Am Board Fam Med; 2012; 25(3):343-9. PubMed ID: 22570398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
    Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
    Azmoon S; Angiolillo DJ
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
    Robinson A; Das K; Koshy SK; Das P
    Future Cardiol; 2009 May; 5(3):237-46. PubMed ID: 19450050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet therapy in acute coronary syndromes.
    Aragam KG; Bhatt DL
    J Cardiovasc Pharmacol Ther; 2011 Mar; 16(1):24-42. PubMed ID: 20924098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Capranzano P; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prasugrel: Clinical development and therapeutic application.
    Guerra DR; Tcheng JE
    Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.
    Yokoi H; Kimura T; Isshiki T; Ogawa H; Ikeda Y
    Thromb Res; 2012 May; 129(5):623-8. PubMed ID: 22178576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
    Wiviott SD
    Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prasugrel as antiplatelet therapy in patients with acute coronary syndromes or undergoing percutaneous coronary intervention.
    Fletcher B; Thalinger KK
    Crit Care Nurse; 2010 Oct; 30(5):45-54. PubMed ID: 20889512
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical profile of prasugrel, a novel thienopyridine.
    Angiolillo DJ; Bates ER; Bass TA
    Am Heart J; 2008 Aug; 156(2 Suppl):S16-22. PubMed ID: 18657682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.
    Martin MT; Spinler SA; Nutescu EA
    Clin Ther; 2011 Apr; 33(4):425-42. PubMed ID: 21635989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?
    Kern MJ
    Catheter Cardiovasc Interv; 2012 Feb; 79(2):255-62. PubMed ID: 22271555
    [No Abstract]   [Full Text] [Related]  

  • 16. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.
    Lyseng-Williamson KA
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):207-16. PubMed ID: 22583148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.
    Baker WL; White CM
    Am J Cardiovasc Drugs; 2009; 9(4):213-29. PubMed ID: 19655817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome. Agents, indications, issues to consider in clinical practice.
    Sibbing D; Orban M; Massberg S
    Hamostaseologie; 2013; 33(1):9-15. PubMed ID: 23299202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the metabolism of clopidogrel and prasugrel.
    Laizure SC; Parker RB
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1417-24. PubMed ID: 20839914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.